No hard information on the fate of Cordis with a JNJ/BSX merger. Potential with BSX pipeline to let them operate in the manner SCIMED has been managed since their buyout. BSX array of products may make them attractive enough with the duplication to add the the JNJ stable. Also, JNJ may weigh the future prospects for Cordis worth less than premium for BSX buyout. Don't have more than rumors. However, news in past and on board has been flat.